Wet AMD: Is combination therapy the way of the future?

Article

Despite recent advances and the promise of new therapies for the treatment of choroidal neovascularization (CNV) resulting from age-related macular degeneration (wet AMD), key challenges remain. These include improving vision outcomes, reducing the numbers of treatments and proving efficacy in different lesion types. While treatment for wet AMD has traditionally centred on monotherapy regimens, the future standard of care may likely focus on combination strategies.

Related Videos
Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network
Baruch Kuppermann, MD, PhD
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns."
Ash Abbey, MD, shares 36-month data from the GALE study of pegcetacoplan
Related Content
Syringes of various sizes, stored in a clinic. Image credit: ©Sergey Ryzhov – stock.adobe.com

Outlook Therapeutics submits UK Marketing Authorisation Application for wet AMD treatment

May 13th 2024
Article

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March

Image credit: ©Vitechek – stock.adobe.com

Going beyond the clinical setting in ophthalmic mentorship

May 9th 2024
Article

Three leaders in glaucoma research, retina care and refractive surgery share their expertise

A single tear on a person's face. Image credit: ©Chepko Danil – stock.adobe.com

ARVO 2024: Non-invasive testing could use tear film to screen for changes in Huntington Disease

May 7th 2024
Article

The mutant huntingtin protein in tear fluid may have the potential to serve as an early marker of changes in Huntington disease

A child has their blood sugar tested using a digital glucometer. Image credit: ©Africa Studio – stock.adobe.com

ARVO 2024: Diabetic retinopathy risk factors in paediatric patients with Type 1 diabetes

May 5th 2024
Article

Study results indicate that maintaining control of blood pressure and hemoglobin A1c are key to preventing the onset of diabetic retinopathy

An illustration shows the central nervous system with long pink lines to indicate sensory information. Image credit: ©Degimages – stock.adobe.com

ARVO 2024: Murine model of multiple sclerosis demonstrates correlation between visual markers and motor-sensory deficits

May 5th 2024
Article

Study data demonstrated a significant correlation between visual function, structure and neurological impairment in an experimental autoimmune encephalomyelitis model

An eye slightly obscured by DNA helix strands. Image credit: ©natali_mis – stock.adobe.com

May is Inherited Retinal Disease Genetic Testing Awareness Month, Prevent Blindness expands on previous weeklong campaign

April 26th 2024
Article

During the month of May, Prevent Blindness will offer fact sheets, videos and other resources for IRD education

© 2024 MJH Life Sciences

All rights reserved.